Anjali R Shah1, Steven Williams2, Caroline R Baumal3, Bernard Rosner4, Jay S Duker3, Johanna M Seddon5. 1. Kellogg Eye Center, University of Michigan Health System, Ann Arbor, Michigan. 2. California Pacific Medical Center, Department of Ophthalmology, San Francisco, California. 3. New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts. 4. Channing Division of Network Medicine, Harvard University, Boston, Massachusetts. 5. New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts. Electronic address: jseddon@tuftsmedicalcenter.org.
Abstract
PURPOSE: To identify factors that influence visual and anatomic response to treatment with intravitreal anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (AMD). DESIGN: Observational cohort study. METHODS: Seventy-two patients were included in this study. Best-corrected Snellen visual acuity (VA) and central foveal thickness measured on optical coherence tomography (OCT) at time of treatment and post-treatment follow-up visits were recorded. Associations between demographic, behavioral, and genetic risk factors and the 2 outcomes were analyzed using mixed-effects linear regression models. Two loci in complement factor H (CFH) were included in a risk score to determine the association between CFH risk and improvement in VA and central foveal thickness. RESULTS: There was a small improvement in VA following anti-VEGF treatment (mean: 3.7 ± 3.0 letters), which was not statistically significant. Significant improvement in VA was observed for the nonrisk CFH Y402H genotype (P < .001) and for a low CFH risk score (P = .019). Regarding the outcome of change in central foveal thickness, improvement was noted in all genotype groups, but reduction after treatment was significantly higher in the low CFH risk score group (P = .033). A significant improvement in mean VA was seen among smokers (P < .001), but this relationship was not observed for central foveal thickness. CONCLUSION: After anti-VEGF therapy, significant improvement in VA was observed for low-risk CFH genotypes and subjects with a low risk score. There was a statistically significant reduction in central foveal thickness overall, and subjects with a low CFH risk score improved more than the high-risk group.
PURPOSE: To identify factors that influence visual and anatomic response to treatment with intravitreal anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (AMD). DESIGN: Observational cohort study. METHODS: Seventy-two patients were included in this study. Best-corrected Snellen visual acuity (VA) and central foveal thickness measured on optical coherence tomography (OCT) at time of treatment and post-treatment follow-up visits were recorded. Associations between demographic, behavioral, and genetic risk factors and the 2 outcomes were analyzed using mixed-effects linear regression models. Two loci in complement factor H (CFH) were included in a risk score to determine the association between CFH risk and improvement in VA and central foveal thickness. RESULTS: There was a small improvement in VA following anti-VEGF treatment (mean: 3.7 ± 3.0 letters), which was not statistically significant. Significant improvement in VA was observed for the nonrisk CFHY402H genotype (P < .001) and for a low CFH risk score (P = .019). Regarding the outcome of change in central foveal thickness, improvement was noted in all genotype groups, but reduction after treatment was significantly higher in the low CFH risk score group (P = .033). A significant improvement in mean VA was seen among smokers (P < .001), but this relationship was not observed for central foveal thickness. CONCLUSION: After anti-VEGF therapy, significant improvement in VA was observed for low-risk CFH genotypes and subjects with a low risk score. There was a statistically significant reduction in central foveal thickness overall, and subjects with a low CFH risk score improved more than the high-risk group.
Authors: Lucia Sobrin; Robyn Reynolds; Yi Yu; Jesen Fagerness; Nicolas Leveziel; Paul S Bernstein; Eric H Souied; Mark J Daly; Johanna M Seddon Journal: Am J Ophthalmol Date: 2010-12-03 Impact factor: 5.258
Authors: Christian Nischler; Hannes Oberkofler; Christoph Ortner; Doris Paikl; Wolfgang Riha; Nora Lang; Wolfgang Patsch; Stefan F Egger Journal: Acta Ophthalmol Date: 2011-01-14 Impact factor: 3.761
Authors: David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: David S Friedman; Benita J O'Colmain; Beatriz Muñoz; Sandra C Tomany; Cathy McCarty; Paulus T V M de Jong; Barbara Nemesure; Paul Mitchell; John Kempen Journal: Arch Ophthalmol Date: 2004-04
Authors: Michael L Klein; Peter J Francis; Bernard Rosner; Robyn Reynolds; Sara C Hamon; Dennis W Schultz; Jurg Ott; Johanna M Seddon Journal: Ophthalmology Date: 2008-06 Impact factor: 12.079
Authors: Johanna M Seddon; Robyn Reynolds; Julian Maller; Jesen A Fagerness; Mark J Daly; Bernard Rosner Journal: Invest Ophthalmol Vis Sci Date: 2008-12-30 Impact factor: 4.799
Authors: Milam A Brantley; Amy M Fang; Jennifer M King; Asheesh Tewari; Steven M Kymes; Alan Shiels Journal: Ophthalmology Date: 2007-12 Impact factor: 12.079
Authors: Laura Lorés-Motta; Moeen Riaz; Michelle Grunin; Jordi Corominas; Freekje van Asten; Marc Pauper; Mathieu Leenders; Andrea J Richardson; Philipp Muether; Angela J Cree; Helen L Griffiths; Connie Pham; Marie-Claude Belanger; Magda A Meester-Smoor; Manir Ali; Iris M Heid; Lars G Fritsche; Usha Chakravarthy; Richard Gale; Martin McKibbin; Chris F Inglehearn; Reinier O Schlingemann; Amer Omar; John Chen; Robert K Koenekoop; Sascha Fauser; Robyn H Guymer; Carel B Hoyng; Eiko K de Jong; Andrew J Lotery; Paul Mitchell; Anneke I den Hollander; Paul N Baird; Itay Chowers Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Adnan H Khan; Charles O Pierce; Gabriella De Salvo; Helen Griffiths; Marie Nelson; Angela J Cree; Geeta Menon; Andrew J Lotery Journal: Eye (Lond) Date: 2021-11-08 Impact factor: 4.456
Authors: Lindsay S Keir; Rachel Firth; Lyndsey Aponik; Daniel Feitelberg; Susumu Sakimoto; Edith Aguilar; Gavin I Welsh; Anna Richards; Yoshihiko Usui; Simon C Satchell; Valeryia Kuzmuk; Richard J Coward; Jonathan Goult; Katherine R Bull; Ruchi Sharma; Kapil Bharti; Peter D Westenskow; Iacovos P Michael; Moin A Saleem; Martin Friedlander Journal: J Clin Invest Date: 2016-12-05 Impact factor: 14.808